| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
|
Cancer Cell
|
2010
|
15.20
|
|
2
|
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
|
N Engl J Med
|
2012
|
10.20
|
|
3
|
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells.
|
Nat Biotechnol
|
2010
|
9.24
|
|
4
|
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
|
Nature
|
2012
|
7.95
|
|
5
|
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
|
Cancer Cell
|
2011
|
7.37
|
|
6
|
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.
|
Cancer Cell
|
2010
|
6.72
|
|
7
|
Comparative isoschizomer profiling of cytosine methylation: the HELP assay.
|
Genome Res
|
2006
|
5.99
|
|
8
|
A molecular roadmap of reprogramming somatic cells into iPS cells.
|
Cell
|
2012
|
4.41
|
|
9
|
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
|
Nature
|
2012
|
4.04
|
|
10
|
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
|
Blood
|
2009
|
4.00
|
|
11
|
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.
|
Nature
|
2011
|
3.63
|
|
12
|
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles.
|
Genome Biol
|
2012
|
3.44
|
|
13
|
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.
|
Nat Genet
|
2012
|
3.33
|
|
14
|
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
|
Nat Med
|
2004
|
3.10
|
|
15
|
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
|
Cancer Cell
|
2010
|
3.05
|
|
16
|
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.
|
PLoS Genet
|
2012
|
2.94
|
|
17
|
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.
|
Nat Immunol
|
2007
|
2.90
|
|
18
|
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
|
Blood
|
2008
|
2.85
|
|
19
|
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.
|
Cell
|
2011
|
2.83
|
|
20
|
Outcome of deferred initial therapy in mantle-cell lymphoma.
|
J Clin Oncol
|
2009
|
2.70
|
|
21
|
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
|
Blood
|
2012
|
2.55
|
|
22
|
CG dinucleotide clustering is a species-specific property of the genome.
|
Nucleic Acids Res
|
2007
|
2.48
|
|
23
|
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
|
Nat Chem Biol
|
2011
|
2.42
|
|
24
|
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
|
Cancer Cell
|
2012
|
2.42
|
|
25
|
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
|
Proc Natl Acad Sci U S A
|
2009
|
2.35
|
|
26
|
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
|
Nat Med
|
2009
|
2.27
|
|
27
|
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
|
Mol Cell
|
2003
|
2.20
|
|
28
|
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
|
Cancer Cell
|
2012
|
2.18
|
|
29
|
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
|
Blood
|
2010
|
2.15
|
|
30
|
Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
|
Proc Natl Acad Sci U S A
|
2007
|
2.06
|
|
31
|
DNMT1-interacting RNAs block gene-specific DNA methylation.
|
Nature
|
2013
|
2.04
|
|
32
|
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
|
Blood
|
2009
|
2.04
|
|
33
|
Induction of sarcomas by mutant IDH2.
|
Genes Dev
|
2013
|
2.02
|
|
34
|
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
|
Cancer Discov
|
2013
|
1.90
|
|
35
|
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
|
Blood
|
2010
|
1.87
|
|
36
|
High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.
|
Nucleic Acids Res
|
2009
|
1.80
|
|
37
|
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.
|
Nat Med
|
2013
|
1.79
|
|
38
|
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.
|
Blood
|
2010
|
1.77
|
|
39
|
An integrative genomic and epigenomic approach for the study of transcriptional regulation.
|
PLoS One
|
2008
|
1.76
|
|
40
|
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.
|
Blood
|
2009
|
1.75
|
|
41
|
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
|
Blood
|
2007
|
1.72
|
|
42
|
Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias.
|
Methods Mol Biol
|
2009
|
1.71
|
|
43
|
Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.
|
Blood
|
2013
|
1.68
|
|
44
|
Kaiso-deficient mice show resistance to intestinal cancer.
|
Mol Cell Biol
|
2006
|
1.67
|
|
45
|
HDAC4 promotes growth of colon cancer cells via repression of p21.
|
Mol Biol Cell
|
2008
|
1.67
|
|
46
|
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.
|
Blood
|
2014
|
1.64
|
|
47
|
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.
|
Blood
|
2010
|
1.53
|
|
48
|
Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.
|
PLoS Genet
|
2013
|
1.50
|
|
49
|
DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis.
|
Cancer Res
|
2010
|
1.49
|
|
50
|
The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.
|
Science
|
2011
|
1.49
|
|
51
|
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
|
Blood
|
2013
|
1.48
|
|
52
|
B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.
|
Curr Opin Hematol
|
2008
|
1.47
|
|
53
|
Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.
|
PLoS Genet
|
2011
|
1.47
|
|
54
|
Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
|
Mol Cell
|
2008
|
1.46
|
|
55
|
CtBP is an essential corepressor for BCL6 autoregulation.
|
Mol Cell Biol
|
2008
|
1.41
|
|
56
|
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.
|
Blood
|
2011
|
1.40
|
|
57
|
Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines.
|
Cancer Res
|
2008
|
1.36
|
|
58
|
Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly.
|
Mol Cell
|
2013
|
1.31
|
|
59
|
Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms.
|
Nat Immunol
|
2013
|
1.30
|
|
60
|
Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.
|
Nat Immunol
|
2013
|
1.28
|
|
61
|
A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.
|
Cell Rep
|
2013
|
1.28
|
|
62
|
An optimized algorithm for detecting and annotating regional differential methylation.
|
BMC Bioinformatics
|
2013
|
1.27
|
|
63
|
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
|
J Clin Oncol
|
2014
|
1.23
|
|
64
|
RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.
|
Cell Rep
|
2013
|
1.22
|
|
65
|
BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.
|
Blood Cells Mol Dis
|
2008
|
1.21
|
|
66
|
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.
|
Blood
|
2003
|
1.19
|
|
67
|
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.
|
Cancer Res
|
2014
|
1.19
|
|
68
|
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia.
|
J Clin Invest
|
2013
|
1.19
|
|
69
|
H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia.
|
Cancer Cell
|
2012
|
1.19
|
|
70
|
BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
|
Blood
|
2009
|
1.15
|
|
71
|
C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.
|
J Clin Invest
|
2012
|
1.14
|
|
72
|
Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis.
|
Proc Natl Acad Sci U S A
|
2010
|
1.14
|
|
73
|
Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.
|
Blood
|
2011
|
1.12
|
|
74
|
Sequential transcription factor targeting for diffuse large B-cell lymphomas.
|
Cancer Res
|
2008
|
1.09
|
|
75
|
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
1.05
|
|
76
|
Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells.
|
Blood
|
2008
|
1.04
|
|
77
|
HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes.
|
Methods Mol Biol
|
2010
|
1.03
|
|
78
|
Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.
|
J Clin Invest
|
2015
|
1.03
|
|
79
|
Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
|
Clin Cancer Res
|
2013
|
1.01
|
|
80
|
Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
|
Leuk Lymphoma
|
2008
|
1.00
|
|
81
|
A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
|
Nature
|
2013
|
0.99
|
|
82
|
Epigenetics and B-cell lymphoma.
|
Curr Opin Hematol
|
2011
|
0.98
|
|
83
|
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
|
J Biol Chem
|
2011
|
0.97
|
|
84
|
Dynamic evolution of clonal epialleles revealed by methclone.
|
Genome Biol
|
2014
|
0.97
|
|
85
|
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
|
Blood
|
2012
|
0.96
|
|
86
|
Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.
|
PLoS One
|
2008
|
0.96
|
|
87
|
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.
|
Biol Blood Marrow Transplant
|
2010
|
0.95
|
|
88
|
Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.
|
Genes Chromosomes Cancer
|
2012
|
0.95
|
|
89
|
DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation.
|
Genome Res
|
2013
|
0.94
|
|
90
|
Downregulation of FOXP1 is required during germinal center B-cell function.
|
Blood
|
2013
|
0.94
|
|
91
|
Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation.
|
Blood
|
2013
|
0.93
|
|
92
|
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.
|
PLoS One
|
2011
|
0.93
|
|
93
|
SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.
|
Blood
|
2012
|
0.92
|
|
94
|
SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells.
|
J Biol Chem
|
2009
|
0.92
|
|
95
|
Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer.
|
ACS Chem Biol
|
2014
|
0.91
|
|
96
|
BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner.
|
J Biol Chem
|
2008
|
0.90
|
|
97
|
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.
|
Blood
|
2012
|
0.90
|
|
98
|
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
|
J Clin Invest
|
2015
|
0.88
|
|
99
|
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia.
|
J Clin Invest
|
2014
|
0.88
|
|
100
|
LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas.
|
Br J Haematol
|
2013
|
0.86
|
|
101
|
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.
|
Clin Cancer Res
|
2010
|
0.86
|
|
102
|
Specific peptides for the therapeutic targeting of oncogenes.
|
Curr Opin Genet Dev
|
2005
|
0.83
|
|
103
|
Molecular pathogenesis of acute promyelocytic leukaemia and APL variants.
|
Best Pract Res Clin Haematol
|
2003
|
0.81
|
|
104
|
Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells.
|
Cancer Res
|
2009
|
0.81
|
|
105
|
Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?
|
Expert Rev Hematol
|
2013
|
0.81
|
|
106
|
Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
|
Crit Rev Oncol Hematol
|
2013
|
0.80
|
|
107
|
Discovering what makes STAT signaling TYK in T-ALL.
|
Cancer Discov
|
2013
|
0.78
|
|
108
|
Targeting lymphomas through MALT1 inhibition.
|
Oncotarget
|
2012
|
0.75
|
|
109
|
Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
|
Nature
|
2016
|
0.75
|